What diseases or symptoms are Lenvatinib/Lenvatinib mainly indicated for?

Lenvatinib is an oral multi-target tyrosine kinase inhibitor widely used in the systemic treatment of a variety of solid tumors. Its main mechanism of action is to inhibit a variety of signaling pathways related to tumor growth and angiogenesis, includingVEGFR, FGFR, PDGFRα, KIT and RET, etc., thereby inhibiting the proliferation, invasion and formation of tumor blood vessels of tumor cells. As a targeted drug, lenvatinib has been approved for the treatment of various cancers around the world, especially in some patient groups where traditional treatment methods are ineffective.

Its earliest approved indication was radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC). This type of thyroid cancer cannot be adequately controlled after receiving iodine-131 treatment. Lenvatinib provides new treatment hope for these patients. In addition, lenvatinib has also become one of the first-line treatment options for advanced liver cancer (HCC), especially in patients who cannot receive local treatment or whose liver function is well preserved. It has shown a certain survival benefit compared with sorafenib. In renal cell carcinoma (RCC), lenvatinib has also been approved for the treatment of advanced RCC in combination with immune checkpoint inhibitors such as pembrolizumab. In addition, lenvatinib is approved for use in patients with endometrial cancer, particularly those whose disease has progressed after prior chemotherapy, often in combination with a PD-1 inhibitor to enhance anti-tumor effects.

It is worth noting that lenvatinib treatment involves multiple systemic targets, so clinical application requires a comprehensive assessment of the patient's tumor type, mutation background, liver and kidney function, and potential side effect tolerance. There are currently more and more studies exploring the potential indications of lenvatinib in gastric cancer, biliary tract cancer, non-small cell lung cancer and other fields, and it is expected to expand its therapeutic scope in the future.

Reference materials:https://www.lenvima.com/